Recently, generic drugs account for a growing proportion of the global small molecule drug market, and the biosimilars are supposed to gain more achievements in the biopharmaceutical field. More importantly, there are an increasing amount of active generic/biosimilar companies are focusing their attention on the development of generics parallel to innovative companies. Therefore, this is critical for many pharmaceutical companies seeking to maximize the value of their products by optimizing the life cycle management (LCM) of branded drugs.
Given the severe drug safety-related issues, there are increasing regulatory requirements governing the post-approval pharmacovigilance. Improving the safety profile of your pharmaceuticals is, therefore, of great importance to your management of product’s lifecycle. Drug adherence and compliance are another complex issue that should be carefully considered because it has a large adverse effect on long-term treatment, resulting in reduced efficiency.
To maximize the lifespan of your existing pharmaceutical products, we will design a detailed protocol and discuss the most valuable development strategies with you. With access to a wide array of specialized technologies, BOC Sciences offers you a variety of new formulation strategies to create successful new products and expand your specificity.
We provide innovative formulation strategies including but not limited to:
BOC Sciences has extensive experiences in cooperation with many bio/pharmaceutical companies to promote products to market quicker and reduce the development costs. We are professional in both the commercialization of innovative pharmaceuticals and life cycle management strategies. Additionally, our experts not only focus on the time period from release to patent expiration, but also participate in your project plan throughout the lifecycle from discovery to retirement.
References